PDCD1 and neoplasm: Given that PD-L1 immune checkpoint protein induced by LMP1 is highly expressed on NPC tumor cells, several Phase I-III clinical studies have been performed, which aim to target the PD-1/PDL-1 pathway in patients with advanced NPC.